Exelixis Inc (EXEL) 3.32 $EXEL
Exelixis' Q1 Loss Widens 67% on Higher Trial and Personnel Costs
Sean Williams, The Motley Fool - Motley Fool - Thu May 01, 6:25PM CDT
A lot of hope is resting on Exelixis ' Cometriq as a possible treatment for metastatic castration-resistant prostate cancer; but tonight was all about the company's first-quarter earnings results . For the quarter, the cancer-focused drug...
Exelixis Announces First Quarter 2014 Financial Results
Business Wire - Thu May 01, 3:13PM CDT
Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the quarter ended March 31, 2014.
Why You Should Watch Exelixis Inc., Geron Corporation and Vertex Pharmaceuticals Today
George Budwell, The Motley Fool - Motley Fool - Thu May 01, 8:01AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Exelixis , Geron , and Vertex Pharmaceuticals today. Exelixis set to release first quarter results today Normally, earnings season for...
Global Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/94xvzp/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - Johnson & Johnson - Sanofi - Novartis AG - AstraZeneca PLC - Astellas Pharma Inc. - Medivation, Inc. - Dendreon Corporation - Takeda Pharmaceutical Company Limited - Exelixis, Inc. - Bristol-Myers Squibb Company - National Cancer Institute - Duke University - The University of Texas M. D. Anderson Cancer Center - University of California, San Francisco - Swiss Group for Clinical Cancer Research - Barbara Ann Karmanos Cancer Institute - NCIC Clinical Trials Group - Memorial Sloan Kettering Cancer Center - University of Southern California For more information visit http://www.researchandmarkets.com/research/94xvzp/metastatic
Global Metastatic Renal Cell Carcinoma Therapeutics Pipeline Review 2014 - Analysis of 23 Companies & 34 Drug Profiles
M2 - Tue Apr 22, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jgdszp/metastatic_renal) has announced the addition of the "Metastatic Renal Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Renal Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Renal Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Renal Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Renal Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - Eli Lilly and Company - Novartis AG - Biocon Limited - Eisai Co., Ltd. - Exelixis, Inc. - Bionomics Limited - Jiangsu Hengrui Medicine Co., Ltd. - Panacea Biotec Limited - Rexahn Pharmaceuticals, Inc. - Debiopharm International S.A. - Acceleron Pharma, Inc. - Argos Therapeutics, Inc. - Cerulean Pharma, Inc. - Immutep S.A. - Syndax Pharmaceuticals, Inc. - TVAX Biomedical, Inc. - Kite Pharma, Inc. - Xiamen Amoytop Biotech Co., Ltd. - Inbiopro Solutions Pvt. Ltd. - Activartis Biotech GmbH - AlphaMab Co., Ltd Drug Profiles - cabozantinib (s)-malate - 177Lu-DOTA-cG250 - AGS-003 - AV0-113 - AZD-2014 - Anti-NY ESO-1 Lymphocytes Vaccine - Autologous Tumor Cell Vaccine [aldesleukin] - BNC-105-P - CRLX-101 - DC-AdGM-CAIX - Debio-0932 - Dendritic Cell Vaccine [aldesleukin] [bevacizumab] [interferon alfa-2b] - IBPM-002-BZ - IMP-321 - LY-2510924 - Mechanism of Action - Orellanine - Product Description - R&D Progress - RX-0201 - SHR-1020 - TVI-Kidney-1 - aldeluskin - bevacizumab biosimilar - bevacizumab biosimilar - bevacizumab biosmilar - dalantercept - decitabine romidepsin - entinostat - everolimus For more information visit http://www.researchandmarkets.com/research/jg...atic_renal
Exelixis to Release First Quarter 2014 Financial Results on Thursday, May 1, 2014
Business Wire - Mon Apr 21, 3:06PM CDT
Exelixis, Inc. (NASDAQ: EXEL) will release its first quarter 2014 financial results on Thursday, May 1, 2014 after the markets close. The announcement will be followed by a live conference call and webcast at 5:00 p.m. EDT/ 2:00 p.m. PDT. During the presentation, Exelixis management will discuss the Company's financial results and provide a general business update.
1 of These 3 Cratering Biotechs is a Buy
George Budwell, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
At the start of the year, the theme seemed to be that biotech was in for another banner year, propelled by a suite of newly launch drugs that would go on to become blockbusters. These rosy prognostications were made despite broad-based biotech funds...
3 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Apr 09, 5:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
European Commission Approves Exelixis Inc.'s Therapy for Thyroid Cancer
ACCESSWIRE - Fri Apr 04, 1:00PM CDT
Exelixis Inc. (NASDAQ:EXEL) enjoyed robust stock volume Apr. 3, with 4,756,727 shares changing hands.
Why I Bought Exelixis
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 04, 11:05AM CDT
Some days as a biotech investor, no matter how savvy you think you are, you just have to bury your head in the sand because you're bound to experience a bad day. That's what happened last week to shareholders of Exelixis , a company I've been very...
Morning Movers in Biotech: Celgene Corporation, Mylan, Inc. and Exelixis, Inc.
George Budwell, The Motley Fool - Motley Fool - Fri Apr 04, 8:00AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Celgene Corporation , Mylan , and Exelixis . Mylan up on possible takeover of rival Swedish Pharma Shares of drugmaker Mylan are up over 11% in...
Are These 3 Biotechs Bad News Buys?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 03, 8:30AM CDT
March wasn't kind to many of biotech's hottest names. From Geron to Exelixis , many of biotech's most talked-about stocks suffered headache-inducing falls over the past month. Biotech's had a good run lately with the market's rise, and while...
Biotech Stock Roundup: Biogen Drug Approved, Exelixis Tumbles on Study Update - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 02, 9:43AM CDT
Biotech companies continued to witness a decline in share prices last week.
Exelixis Continues On
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 31, 6:42PM CDT
Shares of Exelixis got hit hard last week after the company said its clinical trial testing Cometriq in prostate cancer would continue. While the continuation of a trial would normally be a non-event -- we'll get the final data before the end of...
Hot Stock: Exelixis, Shares Gain 5.2% (EXEL)
Comtex SmarTrend(R) - Mon Mar 31, 10:12AM CDT
Exelixis (NASDAQ:EXEL) is one of today's best performing low-priced stocks, up 5.2% to $3.56 on 1.6x average daily volume. Exelixis has traded 7.4 million shares thus far today, vs. average volume of 4.6 million shares per day. The stock has outperformed the Dow (5.2% to the Dow's 0.7%) and outperformed the S&P 500 (5.2% to the S&P's 0.8%) during today's trading.
Which Biotech Blow-Up Is a Bad-News Buy?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sun Mar 30, 1:00PM CDT
On this edition of Market Checkup , Motley Fool health-care analysts David Williamson and Michael Douglass take a look at two of the weeks biggest biotech losers, and why one of them could make an interesting buy today. Shares of Exelixis were...
5 of Last Week's Biggest Losers
Rick Munarriz, The Motley Fool - Motley Fool - Sun Mar 30, 7:30AM CDT
There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers. Company March 28 Weekly Loss Exelixis $3.38 46% MannKind ...
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Mar 29, 7:00AM CDT
Spring might have sprung this week, but plenty of investors aren't feeling warm and fuzzy. That's especially the case for shareholders of this week's three horrendous health0care stocks. One of these stocks disappointed the market by simply...
Why Red Hat, Caesars Entertainment, and Exelixis Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Mar 28, 7:30PM CDT
Favorable economic news helped send the stock market higher despite the usual pre-weekend jitters on Wall Street, as larger gains earlier in the day gave way to traders once again choosing not to hold onto positions in light of geopolitical...
Exelixis Inc's Comet Fails To Dazzle
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri Mar 28, 8:30AM CDT
Astronomers have grown very cautious over the years about predicting which comets will brighten the night skies, as all too many have failed to live up to expectation. Small biotech Exelixis ' own comet, the COMET-1 study of cabozantinib in...
Exelixis' Q1 Loss Widens 67% on Higher Trial and Personnel Costs
Sean Williams, The Motley Fool - Motley Fool - Thu May 01, 6:25PM CDT
A lot of hope is resting on Exelixis ' Cometriq as a possible treatment for metastatic castration-resistant prostate cancer; but tonight was all about the company's first-quarter earnings results . For the quarter, the cancer-focused drug...
Exelixis Announces First Quarter 2014 Financial Results
Business Wire - Thu May 01, 3:13PM CDT
Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the quarter ended March 31, 2014.
Why You Should Watch Exelixis Inc., Geron Corporation and Vertex Pharmaceuticals Today
George Budwell, The Motley Fool - Motley Fool - Thu May 01, 8:01AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Exelixis , Geron , and Vertex Pharmaceuticals today. Exelixis set to release first quarter results today Normally, earnings season for...
Global Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/94xvzp/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - Johnson & Johnson - Sanofi - Novartis AG - AstraZeneca PLC - Astellas Pharma Inc. - Medivation, Inc. - Dendreon Corporation - Takeda Pharmaceutical Company Limited - Exelixis, Inc. - Bristol-Myers Squibb Company - National Cancer Institute - Duke University - The University of Texas M. D. Anderson Cancer Center - University of California, San Francisco - Swiss Group for Clinical Cancer Research - Barbara Ann Karmanos Cancer Institute - NCIC Clinical Trials Group - Memorial Sloan Kettering Cancer Center - University of Southern California For more information visit http://www.researchandmarkets.com/research/94xvzp/metastatic
Global Metastatic Renal Cell Carcinoma Therapeutics Pipeline Review 2014 - Analysis of 23 Companies & 34 Drug Profiles
M2 - Tue Apr 22, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jgdszp/metastatic_renal) has announced the addition of the "Metastatic Renal Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Renal Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Renal Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Renal Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Renal Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - Eli Lilly and Company - Novartis AG - Biocon Limited - Eisai Co., Ltd. - Exelixis, Inc. - Bionomics Limited - Jiangsu Hengrui Medicine Co., Ltd. - Panacea Biotec Limited - Rexahn Pharmaceuticals, Inc. - Debiopharm International S.A. - Acceleron Pharma, Inc. - Argos Therapeutics, Inc. - Cerulean Pharma, Inc. - Immutep S.A. - Syndax Pharmaceuticals, Inc. - TVAX Biomedical, Inc. - Kite Pharma, Inc. - Xiamen Amoytop Biotech Co., Ltd. - Inbiopro Solutions Pvt. Ltd. - Activartis Biotech GmbH - AlphaMab Co., Ltd Drug Profiles - cabozantinib (s)-malate - 177Lu-DOTA-cG250 - AGS-003 - AV0-113 - AZD-2014 - Anti-NY ESO-1 Lymphocytes Vaccine - Autologous Tumor Cell Vaccine [aldesleukin] - BNC-105-P - CRLX-101 - DC-AdGM-CAIX - Debio-0932 - Dendritic Cell Vaccine [aldesleukin] [bevacizumab] [interferon alfa-2b] - IBPM-002-BZ - IMP-321 - LY-2510924 - Mechanism of Action - Orellanine - Product Description - R&D Progress - RX-0201 - SHR-1020 - TVI-Kidney-1 - aldeluskin - bevacizumab biosimilar - bevacizumab biosimilar - bevacizumab biosmilar - dalantercept - decitabine romidepsin - entinostat - everolimus For more information visit http://www.researchandmarkets.com/research/jg...atic_renal
Exelixis to Release First Quarter 2014 Financial Results on Thursday, May 1, 2014
Business Wire - Mon Apr 21, 3:06PM CDT
Exelixis, Inc. (NASDAQ: EXEL) will release its first quarter 2014 financial results on Thursday, May 1, 2014 after the markets close. The announcement will be followed by a live conference call and webcast at 5:00 p.m. EDT/ 2:00 p.m. PDT. During the presentation, Exelixis management will discuss the Company's financial results and provide a general business update.
1 of These 3 Cratering Biotechs is a Buy
George Budwell, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
At the start of the year, the theme seemed to be that biotech was in for another banner year, propelled by a suite of newly launch drugs that would go on to become blockbusters. These rosy prognostications were made despite broad-based biotech funds...
3 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Apr 09, 5:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
European Commission Approves Exelixis Inc.'s Therapy for Thyroid Cancer
ACCESSWIRE - Fri Apr 04, 1:00PM CDT
Exelixis Inc. (NASDAQ:EXEL) enjoyed robust stock volume Apr. 3, with 4,756,727 shares changing hands.
Why I Bought Exelixis
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 04, 11:05AM CDT
Some days as a biotech investor, no matter how savvy you think you are, you just have to bury your head in the sand because you're bound to experience a bad day. That's what happened last week to shareholders of Exelixis , a company I've been very...
Morning Movers in Biotech: Celgene Corporation, Mylan, Inc. and Exelixis, Inc.
George Budwell, The Motley Fool - Motley Fool - Fri Apr 04, 8:00AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Celgene Corporation , Mylan , and Exelixis . Mylan up on possible takeover of rival Swedish Pharma Shares of drugmaker Mylan are up over 11% in...
Are These 3 Biotechs Bad News Buys?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 03, 8:30AM CDT
March wasn't kind to many of biotech's hottest names. From Geron to Exelixis , many of biotech's most talked-about stocks suffered headache-inducing falls over the past month. Biotech's had a good run lately with the market's rise, and while...
Biotech Stock Roundup: Biogen Drug Approved, Exelixis Tumbles on Study Update - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 02, 9:43AM CDT
Biotech companies continued to witness a decline in share prices last week.
Exelixis Continues On
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 31, 6:42PM CDT
Shares of Exelixis got hit hard last week after the company said its clinical trial testing Cometriq in prostate cancer would continue. While the continuation of a trial would normally be a non-event -- we'll get the final data before the end of...
Hot Stock: Exelixis, Shares Gain 5.2% (EXEL)
Comtex SmarTrend(R) - Mon Mar 31, 10:12AM CDT
Exelixis (NASDAQ:EXEL) is one of today's best performing low-priced stocks, up 5.2% to $3.56 on 1.6x average daily volume. Exelixis has traded 7.4 million shares thus far today, vs. average volume of 4.6 million shares per day. The stock has outperformed the Dow (5.2% to the Dow's 0.7%) and outperformed the S&P 500 (5.2% to the S&P's 0.8%) during today's trading.
Which Biotech Blow-Up Is a Bad-News Buy?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sun Mar 30, 1:00PM CDT
On this edition of Market Checkup , Motley Fool health-care analysts David Williamson and Michael Douglass take a look at two of the weeks biggest biotech losers, and why one of them could make an interesting buy today. Shares of Exelixis were...
5 of Last Week's Biggest Losers
Rick Munarriz, The Motley Fool - Motley Fool - Sun Mar 30, 7:30AM CDT
There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers. Company March 28 Weekly Loss Exelixis $3.38 46% MannKind ...
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Mar 29, 7:00AM CDT
Spring might have sprung this week, but plenty of investors aren't feeling warm and fuzzy. That's especially the case for shareholders of this week's three horrendous health0care stocks. One of these stocks disappointed the market by simply...
Why Red Hat, Caesars Entertainment, and Exelixis Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Mar 28, 7:30PM CDT
Favorable economic news helped send the stock market higher despite the usual pre-weekend jitters on Wall Street, as larger gains earlier in the day gave way to traders once again choosing not to hold onto positions in light of geopolitical...
Exelixis Inc's Comet Fails To Dazzle
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri Mar 28, 8:30AM CDT
Astronomers have grown very cautious over the years about predicting which comets will brighten the night skies, as all too many have failed to live up to expectation. Small biotech Exelixis ' own comet, the COMET-1 study of cabozantinib in...
